Results 191 to 200 of about 22,288 (223)

Proteomics of vitreous in neovascular age-related macular degeneration

Experimental Eye Research, 2016
Neovascular age-related macular degeneration (nAMD) has been described as a predominantly inflammatory and proangiogenic retino-choroidal disease. Vitreous humor (VH) is the adjacent and accessible compartment which, due to the vicinity to the retina, might best represent changes of protein-based mediators of nAMD. The aim of this clinical-experimental
Matthias Nobl, Michael Reich, Ivanka Dacheva, Justyna Siwy, William Mullen, Joost P. Schanstra, Chul Young Choi, Jürgen Kopitz, Florian T.A. Kretz, Gerd U. Auffarth, Frank Koch, Michael J. Koss   +11 more
openaire   +3 more sources

Association of neovascular age-related macular degeneration and hyperhomocysteinemia

American Journal of Ophthalmology, 2004
To assess the relationship between plasma homocysteine levels and exudative neovascular age-related macular degeneration (AMD).Cross-sectional study.A prospective comparative cross-sectional study was conducted in outpatient ophthalmology clinics in a university-affiliated medical institution.
Ruth, Axer-Siegel, Dan, Bourla, Rita, Ehrlich, Gad, Dotan, Yoav, Benjamini, Slava, Gavendo, Dov, Weinberger, Ben-Ami, Sela   +7 more
openaire   +2 more sources

Preferred therapies for neovascular age-related macular degeneration

Current Opinion in Ophthalmology, 2011
This report reviews the current treatment strategies and ongoing clinical trials in the treatment of neovascular age-related macular degeneration (AMD).The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison.
Allen, Chiang, Carl D, Regillo
openaire   +2 more sources

Radiation Therapy for Neovascular Age-related Macular Degeneration

International Journal of Radiation Oncology*Biology*Physics, 2013
In the enormity of the public health burden imposed by age-related macular degeneration (ARMD), much effort has been directed toward identifying effective and efficient treatments. Currently, anti-vascular endothelial growth factor (VEGF) injections have demonstrated considerably efficacy in treating neovascular ARMD, but patients require frequent ...
Amar U, Kishan, Bobeck S, Modjtahedi, Lawrence S, Morse, Percy, Lee   +3 more
openaire   +2 more sources

Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2021
Mali Okada, Robert P Finger, Bora Eldem   +2 more
exaly  

Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2022
Peter A Campochiaro, Daniel Miller, Dante J Pieramici   +2 more
exaly  

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data

Ophthalmology, 2020
David Sarraf, K Bailey Freund, Srinivas R Sadda   +2 more
exaly  

Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes

Ophthalmology Retina, 2022
Clement K Chan, Prema Abraham, Wesley T Beaulieu   +2 more
exaly  

Macular atrophy development in neovascular age-related macular degeneration

European Journal of Ophthalmology, 2020
Dan Călugăru, Mihai Călugăru
openaire   +2 more sources

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration

Ophthalmology, 2021
Sobha Sivaprasad, Katie Banister, BEATRIZ Goulão   +2 more
exaly